Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. 1995

S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
Department of Industrial Chemistry, Chiba Institute of Technology, Japan.

Modifications of oligodeoxyribonucleotides include the replacement of the backbone phosphodiester groups with phosphorothioate (S-ODNs) groups and the substitution of phosphorothioate (SO-ODNs) groups at both the 3'- and 5'-ends. In assays for HIV, oligomers (S-ODNs) were more active at the micromolar range than were SO-ODNs of the same sequence. Furthermore, the abilities of antisense-, sense-, random-, and mismatched-oligomers, or homo-oligomers containing internucleotidic phosphorothioate linkages to inhibit HIV-1 replication were examined. Antisense oligonucleotides inhibit the replication and the expression of HIV-1 more efficiently than random-, sense-, mismatched-, and homo-oligomers of the same length or with the same internucleotide modification. Five different target sites (gag, pol, rev, tat, and tar) within the HIV genes were also studied with regard to the inhibition of HIV replication by antisense oligonucleotides. Antisense oligomers complementary to the sites of initiation sequences and to certain splice sites were most effective. The effect of antisense oligomer length on inhibiting viral replication was also investigated. Of particular interest was the S-ODNs-rev 15 mer, which possessed higher anti-HIV activity than the sense-, random-, mismatched-, and homo-20 mers.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013873 Thionucleotides Nucleotides in which the base moiety is substituted with one or more sulfur atoms.
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense

Related Publications

S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
December 1988, Gene,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
August 1994, Proceedings of the National Academy of Sciences of the United States of America,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
October 1995, Antiviral research,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
August 2008, Bioorganic & medicinal chemistry letters,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
September 1993, Antimicrobial agents and chemotherapy,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
August 1998, American journal of ophthalmology,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
January 2001, FEBS letters,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
April 1995, Clinical microbiology reviews,
S G Kim, and T Hatta, and S Tsukahara, and H Nakashima, and N Yamamoto, and Y Shoji, and K Takai, and H Takaku
September 1989, Drugs,
Copied contents to your clipboard!